Previous Close | 1.2500 |
Open | 1.2700 |
Bid | 1.1600 x 3800 |
Ask | 1.1900 x 6800 |
Day's Range | 1.1500 - 1.2891 |
52 Week Range | 0.3450 - 2.1050 |
Volume | |
Avg. Volume | 9,215,022 |
Market Cap | 303.643M |
Beta (5Y Monthly) | 3.74 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript November 9, 2023 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning and welcome to Ocugen’s Third Quarter 2023 Financial Results and Business Update. Please note that this call is being recorded at this time. All participants’ line are in a […]